Women of child-bearing potential and men must agree to practice  highly effective method of contraception and  additional effective (barrier) method of contraception, at the same time, from the time of signing the informed consent through  days (for female patients) and  day (for male patients) after the last dose of study drug, or agree to completely abstain from heterosexual intercourse; should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately; men must agree not to donate sperm during the course of this study or within  days after receiving their last dose of study drug
Effective contraception:\r\n* Women of childbearing potential must agree to practice  effective methods of contraception from the time of signing the informed consent form through  days after the last dose of study therapy, or agree to completely abstain from heterosexual intercourse\r\n* Male subjects, even if surgically sterilized (i.e., status post vasectomy) must agree to  of the following: practice effective barrier contraception during the entire study treatment period and through  days after the last dose of study therapy, or agree to completely abstain from heterosexual intercourse
Male subjects, even if surgically sterilized (i.e., status post-vasectomy), must agree to practice effective barrier contraception during the entire study treatment period and through  days after the last dose of study drug, or agree to completely abstain from heterosexual intercourse
Willingness to use protocol-recommended methods of contraception or to abstain from heterosexual intercourse from start of therapy until at lest  days after the last dose of study therapy
Female patients who:\r\n* Are postmenopausal for at least  year before the screening visit, OR\r\n* Are surgically sterile, OR\r\n* If they are of childbearing potential, agree to practice  effective methods of contraception, at the same time, from the time of signing the informed consent through  days after the last dose of study drug, or agree to completely abstain from heterosexual intercourse
Male patients, even if surgically sterilized (i.e., status post-vasectomy), who:\r\n* Agree to practice effective barrier contraception during the entire study treatment period and through  days after the last dose of study drug, or\r\n* Agree to completely abstain from heterosexual intercourse
Male patients (even those post vasectomy) who are willing to use adequate contraceptive measures or abstain from heterosexual intercourse during the entire study treatment period and for  months after the last dose of study drug
Women who are unwilling, if not postmenopausal or surgically sterile, to abstain from sexual intercourse or employ highly effective contraception from the time of randomization and for at least  days after the last dose of study drug. Men who are unwilling, if not surgically sterile, to abstain from sexual intercourse or employ highly effective contraception from the time of randomization and for at least  days after the last dose of study drug.
Female patients who: are postmenopausal for at least  year before the screening visit, OR are surgically sterile, OR If they are of childbearing potential, agree to practice  effective methods of contraception, at the same time, from the time of signing the informed consent through  months after the last dose of study drug, or agree to completely abstain from heterosexual intercourse.
Male patients, even if surgically sterilized (i.e., status post-vasectomy), who: agree to practice effective barrier contraception during the entire study treatment period and through  months after the last dose of study drug, OR agree to completely abstain from heterosexual intercourse.
Female patients who: Are postmenopausal for at least  year before the screening visit, OR Are surgically sterile, OR If they are of childbearing potential, agree to practice  effective methods of contraception, at the same time, from the time of signing the informed consent through  months after the last dose of study drug, or agree to completely abstain from heterosexual intercourse.
Male patients, even if surgically sterilized (i.e., status post-vasectomy), who: Agree to practice effective barrier contraception during the entire study treatment period and through  months after the last dose of study drug, or Agree to completely abstain from heterosexual intercourse.
Male patients, even if surgically sterilized, should agree to practice effective barrier contraception for the entire study treatment period and through  days after the last dose of the study treatment or agree to completely abstain from heterosexual intercourse. Female patients who are postmenopausal for at least one year before the screening visit or are surgical sterile or if they are of child bearing potential must have a negative pregnancy test within  hours of treatment of the start date and agree to practice two effective methods of contraception forms at the same time from the time of signing the informed consent through  days of the last dose of the study treatment or agree to completely abstain from heterosexual intercourse
Male subject, even if surgically sterilized (i.e., status postvasectomy), agrees to use an acceptable barrier method for contraception (condom with a spermicidal agent), or completely abstain from heterosexual intercourse during the entire study treatment period through  months after the last dose of brentuximab vedotin
Female patients who: are postmenopausal for at least  months before the screening visit, OR; are surgically sterile, OR; if they are of childbearing potential, agree to practice  effective methods of contraception, at the same time,  days prior to starting study drug, during study treatment and for  days after the last dose of study treatment, OR agree to completely abstain from heterosexual intercourse; male patients, even if surgically sterilized (i.e., status post vasectomy), who: agree to practice effective barrier contraception during the entire study treatment period and through  days after the last dose of study treatment, OR; agree to completely abstain from heterosexual intercourse
Women of childbearing potential must agree to practice  effective methods of contraception from the time of signing the informed consent form through  weeks ( half-lives plus  days, the duration of an ovulatory cycle) after the last dose of nivolumab, or agree to completely abstain from heterosexual intercourse
Male subjects, even if surgically sterilized (i.e., status post vasectomy) must agree to  of the following: practice effective barrier contraception during the entire study treatment period and through  weeks ( half-lives plus  days, the duration of sperm turnover) after the last dose of study drug, or completely abstain from heterosexual intercourse
Women of child-bearing potential MUST have a negative serum or urine pregnancy test within  days unless prior hysterectomy or menopause (defined as  consecutive months without menstrual activity); patients should not become pregnant or breastfeed while on this study; women of child-bearing potential must agree to use  highly effective method of contraception and  additional effective (barrier) method, at the same time, from the time of signing the informed consent through  days (or longer, as mandated by local labeling [e.g.; United Surgical Partners International (USPI), Summary of Product Characteristics (SmPC), etc;]) after the last dose of study drug; or agree to practice true abstinence; should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately; male patients, even if surgically sterilized (i.e., status post-vasectomy), who:\r\n* Agree to practice highly effective barrier contraception during the entire study treatment period and through  days after the last dose of study drug, or\r\n* Agree to completely abstain from heterosexual intercourse
Female subject is either postmenopausal for at least  year before the screening visit, is surgically sterilized or if they are of childbearing potential, agree to practice  effective methods of contraception from the time of signing the informed consent form through  days after the last dose of bortezomib, or agree to completely abstain from heterosexual intercourse
Male subjects, even if surgically sterilized (ie, status postvasectomy) must agree to  of the following: practice effective barrier contraception during the entire study treatment period and through a minimum of  days after the last dose of study drug, or completely abstain from heterosexual intercourse
Men of reproductive potential and those who are surgically sterilized (i.e., post-vasectomy) must agree to practice effective barrier contraception or agree to abstain from intercourse while receiving treatment on this study and for at least  months after protocol treatment ends
Female patients must:\r\n* Be postmenopausal for at least  year before the screening visit, OR\r\n* Be surgically sterile, OR\r\n* If they are of childbearing potential, agree to practice  effective methods of contraception, at the same time, from the time of signing the informed consent through  days after the last dose of study treatment, OR agree to completely abstain from heterosexual intercourse
Male patients, even if surgically sterilized (i.e., status post-vasectomy), must:\r\n* Agree to practice effective barrier contraception during the entire study treatment period and through  days after the last dose of study treatment, OR\r\n* Agree to completely abstain from heterosexual intercourse
Male subject, even if surgically sterilized (ie, status postvasectomy), agrees to use an acceptable barrier method for contraception (condom with a spermicidal agent), or completely abstain from heterosexual intercourse during the entire study treatment period through  months after the last dose of alisertib
Female patients who:\r\n* Are postmenopausal for at least  year before the Screening visit, OR\r\n* Are surgically sterile OR\r\n* If they are of childbearing potential, agree to practice  effective methods of contraception at the same time from the time of signing the informed consent through  days after the last dose of study treatment, OR agree to completely abstain from heterosexual intercourse
Male patients, even if surgically sterilized (ie, status postvasectomy), who: must agree to  of the following: practice effective barrier contraception during the entire study treatment period and through a minimum of  days after the last dose of study drug, or completely abstain from heterosexual intercourse
Patients, even if surgically sterilized (i.e., status post vasectomy), who:\r\n* Agree to practice effective barrier contraception during the entire study treatment period and for  months ( days) after the last dose of study drug, or\r\n* Agree to completely abstain from intercourse
Patients, even if surgically sterilized (i.e., status post-vasectomy) must agree to  of the following: practice effective barrier contraception during the entire study treatment period and through a minimum of  days after the last dose of study drug, or completely abstain from heterosexual intercourse if female partner of childbearing age
Male subject agrees to use an acceptable method for contraception during the entire study treatment period through  months after the last dose of MLN; male patients, even if surgically sterilized (ie, status postvasectomy) must agree to practice effective barrier contraception during the entire study treatment period and through four months after the last dose of study drug, or completely abstain from heterosexual intercourse
Male subject agrees to use an acceptable method for contraception during the entire study treatment period through  months after the last dose of MLN; male patients, even if surgically sterilized (i.e., status postvasectomy) must agree to practice effective barrier contraception during the entire study treatment period and through four months after the last dose of study drug, or completely abstain from heterosexual intercourse
Female subject is either postmenopausal for at least  year before the screening visit, is surgically sterilized or if they are of childbearing potential, agree to practice  effective methods of contraception from the time of signing the informed consent form through  days after the last dose of bortezomib, or agree to completely abstain from heterosexual intercourse
Male subjects, even if surgically sterilized (i.e., status postvasectomy) must agree to  of the following: practice effective barrier contraception during the entire study treatment period and through a minimum of  days after the last dose of study drug, or completely abstain from heterosexual intercourse
Female subject is either postmenopausal for at least  year before the screening visit, is surgically sterilized or if they are of childbearing potential, agree to practice  effective methods of contraception from the time of signing the informed consent form through  days after the last dose of bortezomib, or agree to completely abstain from heterosexual intercourse
Male subjects, even if surgically sterilized (ie, status post-vasectomy) must agree to  of the following: practice effective barrier contraception during the entire study treatment period and through a minimum of  days after the last dose of study drug, or completely abstain from heterosexual intercourse
Female patients who: \r\n* Are postmenopausal for at least  year before the screening visit, OR \r\n* Are surgically sterile, OR\r\n* If they are of childbearing potential, (those who are post-menopausal for less than  year) must have negative serum or urine pregnancy test and agree to practice  effective methods of contraception, at the same time, from the time of signing the informed consent through  days after the last dose of study drug, or agree to completely abstain from heterosexual intercourse
Male patients, even if surgically sterilized (i.e., status postvasectomy), who: \r\n* Agree to practice effective barrier contraception during the entire study treatment period and through  days after the last dose of study drug, OR \r\n* Agree to completely abstain from heterosexual intercourse
Female patients who: Are postmenopausal for at least  year before the screening visit, OR Are surgically sterile, OR If they are of childbearing potential, agree to practice  effective methods of contraception, at the same time, from the time of signing the informed consent through  days after the last dose of study drug, or agree to completely abstain from heterosexual intercourse. Male patients, even if surgically sterilized (ie, status postvasectomy), who: Agree to practice effective barrier contraception during the entire study treatment period and through  days after the last dose of study drug, OR Agree to completely abstain from heterosexual intercourse.
Female patient who is of childbearing potential willing to use adequate contraceptive measures while participating on study, OR willing to completely abstain from heterosexual intercourse during the entire study treatment period
Male subject even if surgically sterilized (i.e., status post vasectomy) must agree to practice effective barrier contraception during the entire study treatment period and through  days after the last dose of study treatment, or agree to completely abstain from heterosexual intercourse
Female subjects who:\r\n* Are postmenopausal for at least  year before the screening visit, OR\r\n* Are surgically sterile, OR\r\n* If they are of childbearing potential, agree to practice  effective methods of contraception, at the same time, from the time of signing the informed consent form through  days after the last dose of bortezomib, or agree to completely abstain from heterosexual intercourse
Male subjects, even if surgically sterilized (i.e., status post vasectomy) who:\r\n* Agree to practice effective barrier contraception during the entire study treatment period and through a minimum of  days after the last dose of study drug, OR\r\n* Agree to completely abstain from heterosexual intercourse
Male subject, even if surgically sterilized (i.e., status post-vasectomy), agrees to:\r\n* Use an acceptable method for contraception (effective barrier contraception or:\r\n* Completely abstain from heterosexual intercourse) during the entire study treatment period through  months after the last dose of alisertib
Female patients must meet  of the following:\r\n* Postmenopausal for at least  year before the screening visit, or\r\n* Surgically sterile (have undergone a hysterectomy, bilateral tubal ligation, or bilateral oophorectomy), or\r\n* Females of childbearing potential must agree to practice effective method of contraception from the time of signing the informed consent form through  days after the last treatment dose, or agree to completely abstain from heterosexual intercourse
Male patients, even if surgically sterilized (ie, status post vasectomy) must agree to  of the following:\r\n* Practice effective barrier contraception during the entire study treatment period and through a minimum of  days after the last dose of study drug, or completely abstain from heterosexual intercourse
Women of childbearing potential (WCBP) must have a negative serum or urine pregnancy test within  days of starting study drug; in addition, sexually active WCBP must agree to use adequate contraceptive methods (tubal ligation; intra-uterine device; or barrier contraceptive with spermicide) while on the study; oral, implantable, or injectable contraceptives are not considered effective for this study; WCBP must agree to have pregnancy tests every  weeks while on the study drug; male subject agrees to use an acceptable method of contraception for the duration of the study\r\n* Female patients who:\r\n** Are postmenopausal for at least  year before the screening visit, OR\r\n** Are surgically sterile, OR\r\n** If they are of childbearing potential, agree to practice  effective methods of contraception, at the same time, from the time of signing the informed consent through  days after the last dose of study treatment, OR agree to completely abstain from heterosexual intercourse\r\n* Male patients, even if surgically sterilized (ie, status postvasectomy), who:\r\n** Agree to practice effective barrier contraception during the entire study treatment period and through  days after the last dose of study treatment, OR\r\n** Agree to completely abstain from heterosexual intercourse
For male individuals having intercourse with females of childbearing potential, willingness to abstain from heterosexual intercourse or use a protocol- recommended method of contraception
Male patients, even if surgically sterilized (ie, status postvasectomy), who agree to practice effective barrier contraception during the entire study treatment period and through  days after the last dose of study treatment, or agree to completely abstain from heterosexual intercourse
Female patients who are postmenopausal for at least  year before the Screening visit, or are surgically sterile, or if they are of childbearing potential, must have a negative pregnancy test within  hours of treatment start date and agree to practice  effective methods of contraception, at the same time, from the time of signing the informed consent through  days after the last dose of study treatment, OR agree to completely abstain from heterosexual intercourse
Male patients must agree to practice contraception or to abstain from heterosexual intercourse
Male subjects, even if surgically sterilized (i.e., post-vasectomy) must agree to one of the following: complete abstention from heterosexual intercourse or practice of effective barrier contraception starting at signing of informed consent and continuing through the entire study treatment period and a minimum of  days after the last dose of study drug
Female patients who are post menopausal, surgically sterile, or agree to practice  effective methods of contraception or agree to abstain from heterosexual intercourse; must also adhere to the guidelines of the lenalidomide pregnancy prevention program
Male patients who agree to practice effective barrier contraception or agree to abstain from heterosexual intercourse AND must adhere to the guidelines of the lenalidomide pregnancy prevention program
Female subjects (unless postmenopausal for at least  year before the screening visit, or surgically sterilized), agree to practice two () effective methods of contraception at the same time, or agree to completely abstain from heterosexual intercourse, from the time of signing of the informed consent through  months post-transplant
Male subjects (even if surgically sterilized), of partners of women of childbearing potential must agree to one of the following: practice effective barrier contraception, or abstain from heterosexual intercourse from the time of signing the informed consent through  months post-transplant
Female subjects (unless postmenopausal for at least  year before the screening visit, or surgically sterilized), agree to practice two effective methods of contraception or agree to complete abstain from heterosexual intercourse from the time of signing the informed consent through  months post-transplant
Male subjects (even if surgically sterilized), of partners of women of childbearing potential must agree to practice effective barrier contraception or abstain from heterosexual intercourse from the time of signing the informed consent through  months post-transplant
Female subjects (unless postmenopausal for at least  year before the screening visit, or surgically sterilized), agree to practice two () effective methods of contraception at the same time, or agree to completely abstain from heterosexual intercourse, from the time of signing the informed consent through  months post transplant (see Section .. for definition of postmenopausal).
Male subjects (even if surgically sterilized), of partners of women of childbearing potential must agree to one of the following: practice effective barrier contraception (see Section .. for list of barrier methods), or abstain from heterosexual intercourse from the time of signing the informed consent through  months post transplant.